Respiratory syncytial virus (RSV) infection of HeLa cells induces fusion, but transient expression of the three viral glycoproteins induces fusion poorly, if at all. We found that neuraminidase treatment of RSV-infected cells to remove sialic acid (SA) increases fusion dramatically and that the same treatment of transiently transfected cells expressing the three viral glycoproteins, or even cells expressing the fusion (F) protein alone, results in easily detectable fusion. Neuraminidase treatment of the effector cells, expressing the viral glycoproteins, enhanced fusion while treatment of the target cells did not. Likewise, infectivity was increased by treating virions with neuraminidase, but not by treating target cells. Reduction of charge repulsion by removal of the negatively charged SA is unlikely to explain this effect, since removal of negative charges from either membrane would reduce charge repulsion. Infection with neuraminidase-treated virus remained heparansulfate-dependent, indicating that a novel attachment mechanism is not revealed by SA removal. Interestingly, neuraminidase enhancement of RSV infectivity was less pronounced in a virus expressing both the G and the F glycoproteins, compared to virus expressing only the F glycoprotein, possibly suggesting that the G protein sterically hinders access of the neuraminidase to its fusion-enhancing target.
Introduction
Respiratory syncytial virus (RSV) is a member of the Pneumovirinae subfamily of the Paramyxoviridae family of negative strand RNA viruses (Collins et al., 2001 ). Many of the members of the other subfamily, Paramyxovirinae, have a hemagglutinin-neuraminidase (HN) attachment protein which binds sialic acid (SA) on the surface of target cells (Lamb and Kolakofsky, 2001) . Upon binding to SA, the HN protein is thought to undergo a conformation change and in some way communicate this change to the fusion (F) protein, which then acts to fuse the viral membrane with the target cell membrane. During infection, the neuraminidase function of HN removes SA from cellular glycoproteins and glycolipids, so that the virions produced will not bind to the producer cell or to each other, thereby enhancing their infectivity.
Instead of an HN attachment protein, RSV expresses its glycoprotein (G), which is heavily decorated with O-linked carbohydrate chains and in this way resembles a mucin (Collins, 1990) . The G protein binds glycosaminoglycans, most importantly heparan sulfate (HS), on the surface of target cells to initiate infection (Feldman et al., 1999; Hallak et al., 2000a; Krusat and Streckert, 1997) . The RSV F protein is capable of mediating infectivity without the G or small hydrophobic (SH) glycoproteins (Karron et al., 1997) . In fact, after a virion binds to a target cell, the F protein is capable of efficiently mediating infection and fusion on its own, without any signal from the G protein (Techaarpornkul et al., 2001) .
The mature, cleaved F protein bears three N-linked glycosyl chains (Zimmer et al., 2001) , while the G protein is heavily glycosylated, with 3% of its molecular mass being contributed by N-linked and 55% by O-linked chains (Lambert, 1988) . Both types of carbohydrate chains frequently terminate with SA, linked to galactose or N-acetylgalactosamine residues.
We have observed that neuraminidase treatment greatly enhances syncytium formation in RSV-infected cells and in cells expressing the F protein from a cytoplasmic plasmid. Lambert (Lambert, 1988) reported that neuraminidase treatment of RSV increases infectivity by 50%. However, since the neuraminidase was not removed from the virus preparation before cells were inoculated, it was not clear whether the treatment of the virus or the cells or both was responsible for this effect. Another report indicated that this effect was due to increased binding of neuraminidase-treated virus to target cells (Walter A, 1993) .
The removal of SA from the surface of HIV-infected cells has also been shown to enhance syncytium formation (Sun et al., 2001) . Neuraminidase treatment of HIV virions has been shown to increase their infectivity (Hu et al., 1996) . The increase in infection correlated with increased binding of virions and the removal of charge repulsion was proposed as the mechanism of the enhancement in both of these studies.
We have used a two-population cell-cell fusion assay and a viral infectivity assay to examine the effect of neuraminidase treatment on "effector" cells and virions, and on "target" cells, separately. Our results show that the neuraminidase acts on the effector cell or virus rather than on the target cell. Since the G and F glycoproteins are the only viral proteins involved in RSV attachment and entry (Techaarpornkul et al., 2001) , we compared RSV expressing both proteins with RSV expressing only the F protein.
Neuraminidase treatment had a greater effect on the virus expressing the F protein alone, indicating that its fusionenhancing effect is not on the G protein.
Results

Neuraminidase treatment of infected cells increases syncytium formation
HeLa cells infected with rgRSV-SGF, a recombinant RSV expressing green fluorescent protein (GFP) and all three viral glycoproteins, produce few syncytia by 24 h postinfection (Fig. 1A) . Neuraminidase treatment of these infected cells results in the formation of large syncytia (Fig. 1B) .
A similar effect was observed in HeLa cells transiently expressing the F protein and GFP. GFP expression allows visualization of transfected cells and the syncytia that they form. Very little fusion was observed in these cells 48 h posttransfection (Fig. 1C) . After neuraminidase treatment, syncytia were easily detectable (Fig. 1D) . Cotransfection of the G protein (Fig. 1E) or the G and SH protein (Fig. 1G ) genes along with that of the F protein did not noticeably enhance syncytia formation following neuraminidase treatment ( Fig. 1F and H, respectively) . Similar results were observed in BHK cells and HEp-2 cells (data not shown). We found that transient expression of the F protein alone induced obvious fusion, comparable to that induced by F in the presence of G or G and SH. This is contrary to an earlier report (Heminway et al., 1994) , where neuraminidase was not used, but expression of all three glycoproteins was found to induce much greater fusion than the expression of the F protein alone.
Neuraminidase treatment of the effector or target cells
SA, the terminal sugar residue on most N-and O-linked oligosaccharides, is responsible for much of the negative charge on cell surfaces. On neighboring cells, these negative charges might provide a repulsive force that would work against fusion with a virus-infected cell. The enhanced fusion following neuraminidase treatment might then be due to removal of this repulsive force. If so, removal of SA from either the effector (those expressing the viral F protein) or the target cell would decrease this repulsion and increase fusion.
We examined this possibility in a quantitative two-population fusion assay (Nussbaum et al., 1994; Techaarpornkul et al., 2001) . In this assay, the effector, RSVinfected cells were also infected with recombinant vaccinia v T 7 lacOI expressing T7 polymerase. The target population was infected with another recombinant vaccinia virus, vCB21RlacZ (Alkhatib et al., 1996) , carrying a ␤-galactosidase gene under the control of the T7 polymerase promoter. Fusion between cells of the two populations would allow the T7 polymerase from the effector cell population to drive expression of ␤-galactosidase, whose enzymatic activity is then measured by a colorimetric assay. Since we have previously demonstrated that the SH protein does not enhance fusion (Techaarpornkul et al., 2001) , we compared the effect of neuraminidase treatment of cells infected with rgRSV-GF, which expresses the G and F proteins as its only glycoproteins and rgRSV-F, which expresses the F protein as its only glycoprotein.
Neuraminidase treatment of the rgRSV-GF-infected effector cells caused a fourfold increase in fusion activity ( Fig. 2A) . However, neuraminidase treatment of the target cell population did not enhance fusion. In fact, it had a minor inhibitory effect. Treatment of both populations enhanced fusion also, but not as much as treatment of the effector cells alone. Therefore, removal of SA specifically from the effector cells causes an increase in fusion efficiency.
To examine the role played by the G protein in fusion enhancement by neuraminidase, we tested rgRSV-F-infected effector cells in the same assay. Neuraminidase treatment of the effector cells enhanced fusion sixfold, but neuraminidase treatment of the target cells did not (Fig. 2B) . Neuraminidase treatment of both cell populations also enhanced fusion, but not to the extent that treatment of the effector cells alone did. Fusion enhancement was similar for cells expressing the F protein, whether or not they expressed the G protein, suggesting that the target of the neuraminidase is not the G protein. 
Neuraminidase treatment of virions or target cells
To determine whether neuraminidase has the same effect on virus infectivity as on cell-cell fusion, we diluted stocks of rgRSV-GF and rgRSV-F in serum-free medium and treated them with neuraminidase at 37°C for 1 h. The virus was further diluted in serum-containing medium to minimize the possible effects of the neuraminidase on the target cells. Neuraminidase treatment of virus increased the infectivity of rgRSV-GF by a maximum of 60% compared to untreated virus (Fig. 3A) . This enhancement of infectivity is similar to that seen previously with wild-type RSV expressing all three viral glycoproteins (Lambert, 1988) . The effect of neuraminidase on rgRSV-F infectivity was more dramatic, causing more than a 400% increase in infection at the highest neuraminidase concentration tested. The effect of neuraminidase treatment of both viruses was dose dependent. Similar results were obtained with Vero and HeLa cells (data not shown).
As in the cell-cell fusion assay described above, we treated the target cells with neuraminidase before incubation, in this case to determine whether the removal of SA from the target cells enhanced infectivity. No appreciable increase in the number of infected cells was observed (Fig.  3B ). This result is consistent with that of the cell-cell fusion experiments and confirms that the presence or absence of SA on the surface of target cells has no effect on fusion, in this case resulting in infection. Similar results were obtained for neuraminidase-treated Vero and HeLa cells (data not shown).
Comparison of the effects of neuraminidase and spinoculation on infectivity
Spinoculation probably increases the efficiency of infection by bringing the virus in closer contact with target cells, , and 18 h later with a recombinant vaccinia virus, vT7lacOI, encoding T7 polymerase. To account for background from non-fusionrelated events, control cells were infected with vT7lacOI alone. A second, "target" population was inoculated with recombinant vaccinia virus, vCB21RlacZ, carrying a ␤-galactosidase gene driven by a T7 promoter. Forty-eight hours pi with RSV, either the effector (E) or the target (T) cell population or both were treated with 70 mU/ml neuraminidase for 1 h at 37°C. The target population was removed from the surface using 0.5 mM EDTA and resuspended in OptiMEM, 2% FBS. This population was then overlaid on the effector population and incubated for 3 h at 37°C. The cells were lysed and ␤-galactosidase was assayed by the colorimetric CRPG assay. Background signal (ϭ 0.04 in each case) due to non-fusion-related events was subtracted from each reading. Results show mean values of three samples and are representative of five separate experiments.
perhaps overcoming the repulsive forces between cell and virus. If neuraminidase were to overcome repulsive forces by removing the SA charge, then the effects of these two procedures on infection should be similar. To test this possibility, rgRSV-GF and rgRSV-F viruses were treated with neuraminidase or mock treated before inoculation. After virus addition, one of the plates was centrifuged while the other was not.
After an 18-h incubation at 37°C, the number of infected (green) cells was quantified by flow cytometry (Fig. 4) . In the absence of neuraminidase, spinoculation increased infectivity of both viruses by approximately 400%. The infectivity of rgRSV-GF treated with neuraminidase and spinoculated was similar to that of untreated, spinoculated virus. However, neuraminidase treatment of the virus enhanced rgRSV-F infection following spinoculation by an additional 50%. As shown above, neuraminidase treatment has a greater effect on rgRSV-F infection than on rgRSV-GF infection. Particularly in the case of rgRSV-F, neuraminidase treatment had an additive effect on spinoculation, suggesting that their modes of action differ.
The role of glycosaminoglycans in neuraminidasemediated enhancement of infectivity
To initiate infection of cultured cell lines such as HEp2, RSV binds glycosaminoglycans, particularly HS, on the cell surface. Removal of SA by neuraminidase might enable the virus to use a novel pathway of entry. To examine this possibility, we treated target cells with heparinase I and then inoculated them with virus which had been treated with neuraminidase or not. The treatment of target cells with heparinase I greatly reduced infection (Fig. 5) , consistent with previous results (Hallak et al., 2000a) . Treatment of both viruses with neuraminidase enhanced infection, similar to other results presented here. However, neuraminidase treatment did not compensate for the loss of infectivity caused by the removal of HS from the cell surface. This result clearly indicates that neuraminidase-treated virions still require HS for efficient entry. Therefore, neuraminidase treatment does not appear to allow infection via a novel receptor.
Exposed galactose residues in enhancement of infection
SA residues are linked by ␣2-3 or ␣2-6 glycosidic bonds to subterminal galactose or N-acetylgalactosamine residues on oligosaccharide chains. When SA is removed by neuraminidase treatment, these residues are exposed. Per- Fig. 4 . The effect of neuraminidase treatment and spinoculation on infectivity. rgRSV-GF or rgRSV-F was treated with 70 mU/ml neuraminidase or mock treated and used to inoculate cells in two parallel plates. One plate was spun at 1700g for 15 min at 4°C, while the other was not. After incubation at 37°C for 20 h, the number of infected cells was counted by flow cytometry. The number of infected cells is represented as a fold increase in infection, which was calculated as the ratio of the number of cells infected after treatment (with neuraminidase or spinoculation or both) to the number of cells infected after mock neuraminidase treatment. Results are representative of three independent experiments. Fig. 5 . The effect of heparinase I treatment of cells prior to inoculation with neuraminidase-treated rgRSV-GF or rgRSV-F. Virus was treated with 70 mU/ml neuraminidase for 1 h at 37°C or mock treated. HEp2 cells were treated with 2 mIU/ml heparinase I for 2 h at 18°C. The heparinase was removed and the cells were washed and inoculated with virus. After incubation at 37°C for 20 h, the number of infected cells in a 10ϫ field were counted. Six random fields were counted in each case.
haps it is these newly revealed carbohydrates on the viral surface that enable the virus to bind to receptors for these sugars on the target cell surface. To test this possibility, we treated rgRSV-GF and rgRSV-F with neuraminidase and then inoculated cells in the presence of increasing amounts of D-galactose or N-acetylgalactosamine (Fig. 6 ) which should compete for binding to galactose or galactosamine receptors. In the case of desialylyated HIV gp120, these sugars compete for binding to the galactose receptors on human dendritic cells and monocytes at a concentration of 10 mM (Manca, 1992) . In our experiments, neither of these sugars decreased the infectivity of neuraminidase-treated virus or untreated virus at concentrations of up to 40 mM. Therefore, the exposure of the subterminal galactose or N-acetylgalactosamine residues does not seem to be involved in the enhanced infection after neuraminidase treatment of the viruses. Similar results were obtained with multivalent BSA-lactosyl and BSA-N-acetylgalactosamide complexes (data not shown).
Effect of neuraminidase treatment on virus binding
Neuraminidase enhancement of fusion and infection could be due to an enhancement of either binding or fusion.
To test the effect of neuraminidase treatment on virion binding, we metabolically labeled both rgRSV-GF and rgRSV-F virions with [
35 S]methionine and cysteine, purified them twice over linear sucrose gradients, and used them in a binding assay, as previously described (Techaarpornkul et al., 2001) . As observed before, rgRSV-GF virions bind cells much more effectively than rgRSV-F virions (Fig.  7A) , due to the presence of the G protein, which is principally responsible for binding to heparan sulfate on cells (Techaarpornkul et al., 2001 (Techaarpornkul et al., , 2002 .
Purified virions were treated with neuraminidase and their binding to target cells was compared to that of mocktreated virions (Fig. 7A) . rgRSV-GF virions bound 10% (P ϭ 0.08, analysis of variance, ANOVA) more efficiently, and rgRSV-F virions bound 50% (P ϭ 0.003, ANOVA) more efficiently when treated with neuraminidase. However, this enhanced binding can account for only a portion of the enhanced infectivity (Fig. 7B) . The binding of rgRSV-GF increased by 10%, while its infectivity increased by 70%. Similarly, the binding of rgRSV-F increased by 50%, while its infectivity increased by 140%. These results suggest that in addition to binding, neuraminidase treatment also enhances a postbinding step, possibly fusion. 
Effect of neuraminidase on the state of virion aggregation
Neuraminidase treatment could increase infectivity if it were to disaggregate viral particles. If virions disaggregate, the particle size would decrease and consequently their migration in a sucrose velocity gradient would also decrease. To test this possibility, we used 35 S-metabolically labelled rgRSV-GF and rgRSV-F, which had been purified twice by sucrose density gradient. Purified virions were treated with neuraminidase or mock treated and layered on top of a 15-45% linear sucrose gradient and centrifuged at 15,000g for 10 min. Fractions were collected and the cpm in each fraction were determined in a beta-counter (Fig. 8) . Neuraminidase-treated virus separated in a pattern similar to that of mock-treated virus, indicating that neuraminidase treatment did not disaggregate virions.
Discussion
RSV infection of cultured cells results in fusion, generating multinucleated syncytia. This cell-cell fusion process is similar to the virus-cell fusion that initiates infection and is, as such, an important tool for assessing F protein function. In this report we show that neuraminidase treatment of RSV-infected cells dramatically increases fusion. Neuraminidase treatment was previously shown to increase the infectivity of HIV-1 (Hu et al., 1996) and to increase syncytium formation in cultures of cells infected with HIV-1 (Sun et al., 2001 ). The most likely explanation appeared to be the removal of repulsive negative charges from either surface since neuraminidase treatment of either the effector or the target surface increased infectivity. In our experiments on RSV-induced fusion, removal of SA from the effector, but not the target surface, enhanced fusion. In fact, removal of SA from the target cells actually had a negative effect on cell-cell fusion. The cause of this negative effect is not clear. Likewise, spinoculation, which likely overcomes charge repulsion by centrifugal force, greatly enhanced virus infection, but did not supplant the neuraminidase effect. These results suggest that the neuraminidase effect is not due to a general removal of charge repulsion between effector and target surfaces.
Another possible explanation is that exposure of the penultimate sugar residue, galactose or N-acetylgalactosamine, on the effector membrane allows binding to a galectin receptor on target cells. We do not specifically know whether the cells used in this study express galectin receptors, but one such molecule, the asialoglycoprotein receptor, is expressed at a high level on the hepatoma cell line, HepG2 (Ashwell and Morell, 1974) . However, we found that neuraminidase treatment of RSV increased in- Fig. 8 . The effect of neuraminidase treatment on velocity sedimentation of rgRSV-GF and rgRSV-F.
35 S-labeled virus twice-purified through a sucrose gradient was mock treated or treated with 70 mU/ml neuraminidase for 1 h at 37°C and then layered on top of a 15-45% linear sucrose gradient. After centrifugation at 15,000g for 10 min, fractions were collected from the bottom of the tube, and cpm were determined in a betacounter. 35 S-labeled virus, twice-purified through a sucrose gradient, was mock treated or treated with 60 mU/ml neuraminidase for 1 h at 37°C and then incubated with confluent monolayers of HeLa cells (20,000 cpm/well) for 1 h at 4°C. Unbound virus was removed by washing four times with cold medium. (A) To assess binding, the cells were lysed in RIPA buffer and bound radioactivity was counted using a beta-counter. Difference in the neuraminidase-treated and untreated rgRSV-F virions (P Ͻ 0.05 as determined by an analysis of variance (ANOVA) test). By the same test, the increase in rgRSV-GF virion binding was not significant (P ϭ 0.08). (B) To assess infectivity, growth medium was added and after incubation at 37°C for 20 h the number of infected cells per field was counted, using the 10ϫ objective of an inverted fluorescence microscope. fectivity to similar levels for both HEp2 and HepG2 cells (N. Barretto and M. Peeples, unpublished data), suggesting that galectin binding is not involved in the enhancement of fusion and infection. This result concurs with the failure of soluble galactose and N-acetylgalactosamine to block infection. Furthermore, neuraminidase-treated virus remained dependent on HS for infectivity, indicating that an additional HS-independent attachment mechanism is not involved. Neuraminidase treatment slightly increased the binding of rgRSV-GF and rgRSV-F virions to target cells, but this was not sufficient to account for the increase in infection, indicating that neuraminidase also enhances a step other than binding.
Neuraminidase treatment of both rgRSV-GF-and rgRSV-F-infected cells greatly enhanced their ability to fuse with neighboring cells, indicating that the G protein is not the important target for the fusion-enhancing effect of the neuraminidase. Neuraminidase treatment of rgRSV-F virions had a similar enhancing effect but, surprisingly, the same treatment of rgRSV-GF virions had a much less dramatic effect. These findings suggest that the glycoprotein packing in the virions may decrease the access of the neuraminidase to the critical SA residue(s) on the G or F protein.
Of course, we cannot rule out the possibility that these critical SA residues are on other host-derived glycoproteins and glycolipids on the virion surface. Removal of SA from host-derived molecules may serve to decrease steric hindrance between the viral and the cellular membranes involved in the fusion event.
The three N-glycosyl chains on the mature F protein have been shown to modulate its fusion activity (Zimmer et al., 2001) . Mutations that remove them individually affect fusion without affecting cell-surface expression of the F protein (Zimmer et al., 2001) . Removal of the N70 chain on F2 caused a 40% increase in fusion. Perhaps removal of just the terminal SA on this chain would also result in more efficient fusion. Removal of the N500 carbohydrate chain on the F1 subunit completely destroyed fusion activity. This chain lies within the HR2 (helical repeat 2) region, which is involved in the formation of the 6-helix bundle (LawlessDelmedico et al., 2000; Zhao et al., 2000) during fusion. Perhaps this chain is involved in maintaining conformation or stabilizing the helical repeat, such that its complete removal is lethal. However, removal of just the SA residue from the terminus of this chain might enhance fusion.
Like the attachment proteins of many paramyxoviruses, the G protein might express endogenous neuraminidase activity or esterase activity, which would remove or destroy some of the SA on the virion. In that case, exogenously supplied neuraminidase might not have a noticeable effect on fusion, unless the G protein is absent. The finding that the fusion of rgRSV-GF-infected cells is enhanced by neuraminidase to a similar extent as rgRSV-F-infected cells argues against this possibility. Furthermore, we were unable to detect any neuraminidase or esterase activity associated with the G protein in virions (N. Barretto and M.E. Peeples, unpublished data).
In summary, we have shown that neuraminidase treatment increases cell-cell fusion in virus-infected cells and virus-cell fusion. This effect is due to the removal of sialic acid residues from the effector cells or virus only. Removal of the negatively charged sialic acid from these surfaces may allow slightly more efficient binding to heparan sulfate on the surface of target cells, perhaps by reducing electrostatic repulsion. However, better binding accounts for only a portion of the increase in infectivity, suggesting that another step, probably fusion, is also enhanced. Neuraminidase treatment also enabled us to detect fusion in cells transiently expressing the F protein, with or without the G protein. Before neuraminidase treatment, we had been unable to detect fusion in these cells. This finding should facilitate the study of the fusogenic activity of F protein mutants. Furthermore, the infectivity of RSV stock virus, particularly viruses containing F as their only glycoprotein, can be increased by treatment with neuraminidase. We have also shown that spinoculation of cultured cells can be used to dramatically increase the infectivity of RSV. Spinoculation has been previously shown to increase the infectivity of HIV-1 through the enhancement of binding (O'Doherty et al., 2000) .
In vivo, neuraminidases produced by viruses, bacteria, and fungi, such as influenza and parainfluenza viruses, Pseudomonas aeruginosa, Streptococcus, Pneumococcus, Cryptococcus, and Pneumocystis carinii may affect the course of RSV disease in coinfections of the respiratory tract. Some of these organisms are opportunistic pathogens in immunocompromised individuals. The neuraminidase they produce could enhance RSV infection, spread, and disease, which is known to be particularly severe in these patients (Fishaut et al., 1980; Hertz et al., 1989; Krinzman et al., 1998) .
Materials and methods
Cells and viruses
HEp2, Vero, HeLa, and BHK-21 cells were obtained from the American Type Culture Collection. HEp2 cells were maintained in OptiMEM (Gibco, Invitrogen, Carlsbad, CA) 2% fetal bovine serum (FBS). Vero cells were maintained in RPMI 1640 (Gibco), 5% FBS. HeLa and BHK-21 cells were maintained in DMEM (Gibco), 10% FBS. All cells were incubated at 37°C, 5% CO 2 .
Virus was grown in HEp2 or HeLa cells and titrated on the same cells. For titration, 10-fold dilutions of the virus were made in OptiMEM, 2% FBS. Twenty microliters of each dilution was added to cells in a 96-well plate. After incubation for 1 h with rocking, inocula were removed and replaced by OptiMEM, 2% FBS. Cells were incubated for 18 -24 h at 37°C before observation. The number of green cells in each well was counted under an inverted focus fluorescent microscope. Titers were calculated taking into account dilution factors and volumes used for inoculation and expressed in pfu/ml.
Construction and rescue of recombinant RSV expressing all three viral glycoproteins (rgRSV-SGF) and the enhanced GFP was described previously (Hallak et al., 2000b) Mutants of this virus lacking the gene for the SH protein (rgRSV-GF) or lacking the genes for both the SH and the G proteins (rgRSV-F) have been described (Techaarpornkul et al., 2001 ).
Neuraminidase treatment
Viruses or cells were treated with neuraminidase from Clostridium perfringens (Sigma Chemicals, St. Louis, MO) diluted in serum-free OptiMEM in the presence of the protease inhibitors leupeptin (0.5 g/ml), aprotinin (10 g/ ml), and PMSF (1 mM). Treatment was carried out at 37°C, 5% CO 2 , for 1 h. The sample was then diluted by the addition of serum-containing medium to neutralize the neuraminidase before cells were inoculated.
Spinoculation
Virus was diluted in OptiMEM, 2% FBS, and 0.4 ml was added to each well of a 12-well plate. Plates were spun at 1750g for 15 min at 4°C in a Sorvall RT6000B centrifuge and transferred to 37°C, 5% CO 2 , for 30 min. The inoculum was removed and replaced by OptiMEM, 2% FBS. Plates were incubated at 37°C for 20 h. The cells were removed from the plastic with trypsin and fixed, and the fluorescent green cells were counted by flow cytometry.
Heparinase I treatment of cells
Cells were rinsed with PBS and incubated with 2 mIU/ml heparinase I (Sigma Chemicals) diluted in OptiMEM, 2% FBS, containing protease inhibitors at 18°C for 2 h. Heparinase was removed and the cells were rinsed three times with PBS before addition of the inoculum.
Fusion assay
Cell-cell fusion was assayed as described (Nussbaum et al., 1994) , with minor modifications (Techaarpornkul et al., 2001) . Briefly, effector HeLa cells in a 48-well plate were inoculated with rgRSV-GF or rgRSV-F, incubated for 24 h, and superinfected at an m.o.i. of 5 with vT7lacOI, a recombinant vaccinia encoding T7 polymerase under the control of a lacinducible promoter (Alexander et al., 1992) . One hour later the medium was replaced with medium containing 0.1 mM isopropyl-1-thio-␤-D-galactoside. Target HeLa cells were infected with vCB21RlacZ (Alkhatib et al., 1996) , a recombinant vaccinia encoding ␤-galactosidase under the control of a T7 promoter at an m.o.i of 5-10 and incubated for 18 h. To account for non-fusion-related background, control effector cells were infected with vT7lacOI alone. At 36 h after the initial RSV infection, RSV-infected effector cells or control effector cells were either treated with neuraminidase (70 mU/ml) or not. Alternatively, the vCB21RlacZ-infected cells were treated with neuraminidase or not. The vCB21RlacZ-infected target cell population was removed from the surface of the dishes using Versene (Invitrogen), rinsed once with OptiMEM, 2% FBS, 250 mM CaCl 2 , and twice with OptiMEM, 2% FBS, before being resuspended at 3 ϫ 10 6 cells/ml. A total of 200 l of the target cells were then overlaid on the RSV-infected effector cells. The populations were incubated together for 3 h before being lysed by the addition of 5 l 10% NP-40. A total of 50 l of the lysate was mixed with 50 l CRPG (chlorophenol-red-␤-D-galactopyranoside; Boehringer Mannheim) 16 mM CRPG, 0.12 M Na 2 HPO 4 · H 2 O, 0.08 M NaH 2 PO 4 · H 2 O, 0.02 M KCl, 0.002 M MgSO 4 · 7H 2 O, 0.01 M ␤-mercaptoethanol) in a 96-well flat-bottom plate. After incubation at 20°C for 1 h, the intensity of the yellow color was determined at 570 nm on a plate reader (Ceres UV 900 Hdi: Biotek Instruments, Inc.). Control values were subtracted from experimental values before plotting.
Binding assay
HeLa cells were inoculated with rgRSV-GF or rgRSV-F. After 24 h, the medium was replaced with DMEM lacking methionine and cysteine (Gibco), supplemented with 100 uCi/ml [ 35 S]methionine and [ 35 S]cysteine (Trans 35 S-Label, ICN). The virus was harvested after a 24-h labeling period. The virus was then purified twice by ultracentrifugation through linear sucrose gradients (25 to 55%). Fractions of 1 ml were collected manually in the region of 35-40% sucrose, and the cpm in each fraction was counted. Fractions containing the highest cpm were pooled.
For the binding assay, 20,000 cpm/well of virus was suspended in MEM (Gibco) and treated with 60 mU/ml neuraminidase, or not, for 1 h at 37°C. Bovine serum albumin was added to a final concentration of 1% and the virus was added to HeLa cells in a 24-well plate and incubated for 1 h at 4°C. The inoculum was then removed and the cells were rinsed three times with cold PBS, lysed in 100 l RIPA buffer, and analyzed in a scintillation counter (Beckman LS5000TD).
Velocity gradient sedimentation
Purified, 35 S-labeled rgRSV-GF and rgRSV-F were prepared as in the previous section. Virus was suspended in MEM and treated with 60 mU/ml neuraminidase or mock treated for 1 h at 37°C. The treated virus was then laid on top of 15-45% linear sucrose gradients. The gradients were centrifuged at 11,000 rpm for 10 min at 10°C using a SW27 rotor in an ultracentrifuge (Beckman). Fractions of 1.5 ml were collected from the bottom of the tube using a fraction collector (Gilson, Middleton, WI) and analyzed in a scin-tillation counter. The sucrose concentration of each fraction was determined using a refractometer (Bausch and Lomb).
Plasmids
The F and G genes of RSV were PCR amplified from the infectious cDNA clone and inserted into the NcoI and BamHI sites of the vector pTM1 (Moss et al., 1990) , downstream of the T7 promotor. The pTM1 plasmid encoding the SH gene was HG122. The humanized Renilla green fluorescent protein, R-GFP (Stratagene), was similarly cloned into pTM1.
Fluorescence microscopic analysis of syncytium formation
HeLa cells were cotransfected with pTM1-GFP and pTM1-F alone, or along with pTM1-G and pTM1-SH, using HeLa Monster reagent (Mirus, Panvera, Madison, WI). The cells were infected with recombinant vaccinia virus, vTF7-3 (Fuerst et al., 1987) . After 48 h, the cells were either treated with 200 mU/ml neuraminidase, or not, for 45 min at 37°C. The cells were then viewed under an inverted fluorescence microscope (Nikon Optiphot) and photographed with a digital camera (Roper Scientific).
